Effect of relapses on development of residual deficit in multiple sclerosis

被引:279
作者
Lublin, FD
Baier, M
Cutter, G
机构
[1] Mt Sinai Med Ctr, Corinne Goldsmith Dickinson Ctr Multiple Sclerosi, New York, NY 10029 USA
[2] Cooper Inst, Denver, CO USA
[3] Univ Nevada, Reno, NV 89557 USA
关键词
D O I
10.1212/01.WNL.0000096175.39831.21
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the percentage of patients with residual deficits following multiple sclerosis ( MS) exacerbations and the magnitude of those deficits using a database of pooled placebo patients from clinical trials. Methods: A database of patients assigned to the placebo group in several randomized clinical trials was queried to determine those patients with Expanded Disability Status Scale ( EDSS) and Scripps Neurologic Rating Scale assessments prior to, at the time of, and after an acute exacerbation of MS. The extent of deficit present at these time points was compared to determine the acute effect of exacerbations and the degree of persistent disability. Results: Forty- two percent of patients had residual deficit of at least 0.5 and 28% had residual of greater than or equal to 1.0 EDSS units, at an average of 64 days after an exacerbation. The results were reproduced across subsequent exacerbations and were sustained over time. The subgroup of patients with measurable change in EDSS during the exacerbation had more extensive residual impairment on the follow- up visits. Similar results were seen when the Scripps score was examined. Conclusion: MS exacerbations produce a measurable and sustained effect on disability.
引用
收藏
页码:1528 / 1532
页数:5
相关论文
共 14 条
  • [1] Relapses and progression of disability in multiple sclerosis.
    Confavreux, C
    Vukusic, S
    Moreau, T
    Adeleine, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) : 1430 - 1438
  • [2] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
    Confavreux, C
    Vukusic, S
    Adeleine, P
    [J]. BRAIN, 2003, 126 : 770 - 782
  • [3] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    [J]. BRAIN, 1999, 122 : 871 - 882
  • [4] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [5] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [6] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis
    Jacobs, LD
    Cookfair, DL
    Rudick, RA
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Goodkin, DE
    Granger, CV
    Simon, JH
    Alam, JJ
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeinstockGuttman, B
    Whitman, RH
    Baird, WC
    Fillmore, M
    Bona, LM
    ColonRuiz, ME
    Nadine, BS
    Donovan, A
    Bennett, S
    Kieffer, YM
    Umhauer, MA
    Miller, CE
    Kilic, AK
    Sargent, EL
    Schachter, M
    Shucard, DW
    Weider, V
    Catalano, BA
    Cervi, JM
    Czekay, C
    Farrell, JL
    Filippini, JS
    Matyas, RC
    Michienzi, KE
    Ito, M
    OMalley, JA
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (03) : 285 - 294
  • [7] COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    JOHNSON, KP
    BROOKS, BR
    COHEN, JA
    FORD, CC
    GOLDSTEIN, J
    LISAK, RP
    MYERS, LW
    PANITCH, HS
    ROSE, JW
    SCHIFFER, RB
    VOLLMER, T
    WEINER, LP
    WOLINSKY, JS
    BIRD, SJ
    CONSTANTINESCU, C
    KOLSON, DL
    GONZALEZSCARANO, F
    BRENNAN, D
    PFOHL, D
    MANDLER, RN
    ROSENBERG, GA
    JEFFREY, C
    BARGER, GR
    GANDHI, B
    MOORE, PM
    ROGERS, LR
    LISAK, D
    SMITH, L
    ELLISON, GW
    BAUMHEFNER, RW
    CRAIG, SL
    JALBUT, SS
    KATZ, E
    CONWAY, KL
    BURNS, JB
    SHIBA, C
    GIANG, DW
    PETRIE, MD
    GUARNACCIA, JB
    ANDERSON, S
    MCKEON, A
    MCCARTHY, M
    THOMAS, AB
    VRIESENDORP, FJ
    AUSTIN, SG
    LINDSEY, JW
    DIMACHKIE, M
    CERRETA, E
    KACHUCK, N
    MCCARTHY, KA
    [J]. NEUROLOGY, 1995, 45 (07) : 1268 - 1276
  • [8] KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
  • [9] Defining the clinical course of multiple sclerosis: Results of an international survey
    Lublin, FD
    Reingold, SC
    [J]. NEUROLOGY, 1996, 46 (04) : 907 - 911
  • [10] Medical progress: Multiple sclerosis.
    Noseworthy, JH
    Lucchinetti, C
    Rodriguez, M
    Weinshenker, BG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) : 938 - 952